SuRo Capital Valuation
Is SSSS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SSSS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SSSS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SSSS's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SSSS?
Key metric: As SSSS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is SSSS's PS Ratio? | |
|---|---|
| PS Ratio | 19.4x |
| Sales | US$5.90m |
| Market Cap | US$114.08m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 26.3x |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SSSS's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.5x | ||
ENDI CrossingBridge Advisors | 7.4x | n/a | US$70.8m |
WHG Westwood Holdings Group | 1.5x | n/a | US$135.8m |
STGC StartEngine Crowdfunding | 3.9x | n/a | US$108.2m |
HGBL Heritage Global | 1.2x | 12.0% | US$59.2m |
SSSS SuRo Capital | 19.4x | -24.3% | US$114.1m |
Price-To-Sales vs Peers: SSSS is expensive based on its Price-To-Sales Ratio (19.4x) compared to the peer average (3.5x).
Price to Sales Ratio vs Industry
How does SSSS's PS Ratio compare vs other companies in the US Capital Markets Industry?
Price-To-Sales vs Industry: SSSS is expensive based on its Price-To-Sales Ratio (19.4x) compared to the US Capital Markets industry average (3.2x).
Price to Sales Ratio vs Fair Ratio
What is SSSS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 19.4x |
| Fair PS Ratio | 1.4x |
Price-To-Sales vs Fair Ratio: SSSS is expensive based on its Price-To-Sales Ratio (19.4x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$4.91 | US$6.80 +38.5% | 16.4% | US$8.70 | US$6.00 | n/a | 4 |
| Nov ’25 | US$4.62 | US$6.68 +44.5% | 17.5% | US$8.70 | US$6.00 | n/a | 4 |
| Oct ’25 | US$3.97 | US$6.43 +62.0% | 21.4% | US$8.70 | US$5.00 | n/a | 4 |
| Sep ’25 | US$3.95 | US$6.43 +62.7% | 21.4% | US$8.70 | US$5.00 | n/a | 4 |
| Aug ’25 | US$3.95 | US$6.69 +69.3% | 27.1% | US$9.75 | US$5.00 | n/a | 4 |
| Jul ’25 | US$3.95 | US$6.69 +69.3% | 27.1% | US$9.75 | US$5.00 | n/a | 4 |
| Jun ’25 | US$4.16 | US$6.69 +60.8% | 27.1% | US$9.75 | US$5.00 | n/a | 4 |
| May ’25 | US$3.76 | US$6.69 +77.9% | 27.1% | US$9.75 | US$5.00 | n/a | 4 |
| Apr ’25 | US$4.42 | US$6.69 +51.3% | 27.1% | US$9.75 | US$5.00 | n/a | 4 |
| Mar ’25 | US$4.30 | US$6.56 +52.6% | 28.6% | US$9.75 | US$5.00 | n/a | 4 |
| Feb ’25 | US$3.73 | US$6.56 +75.9% | 28.6% | US$9.75 | US$5.00 | n/a | 4 |
| Jan ’25 | US$3.94 | US$6.56 +66.6% | 28.6% | US$9.75 | US$5.00 | n/a | 4 |
| Dec ’24 | US$4.00 | US$6.56 +64.1% | 28.6% | US$9.75 | US$5.00 | n/a | 4 |
| Nov ’24 | US$4.20 | US$6.38 +51.8% | 24.4% | US$9.00 | US$5.00 | US$4.62 | 4 |
| Oct ’24 | US$3.62 | US$6.38 +76.1% | 24.4% | US$9.00 | US$5.00 | US$3.97 | 4 |
| Sep ’24 | US$3.61 | US$6.38 +76.6% | 24.4% | US$9.00 | US$5.00 | US$3.95 | 4 |
| Aug ’24 | US$4.06 | US$6.38 +57.0% | 24.4% | US$9.00 | US$5.00 | US$3.95 | 4 |
| Jul ’24 | US$3.20 | US$6.38 +99.5% | 24.4% | US$9.00 | US$5.00 | US$3.95 | 4 |
| Jun ’24 | US$3.30 | US$6.38 +93.2% | 24.4% | US$9.00 | US$5.00 | US$4.16 | 4 |
| May ’24 | US$3.65 | US$6.38 +74.7% | 24.4% | US$9.00 | US$5.00 | US$3.76 | 4 |
| Apr ’24 | US$3.62 | US$7.00 +93.4% | 25.4% | US$9.50 | US$5.50 | US$4.42 | 3 |
| Mar ’24 | US$3.64 | US$7.33 +101.5% | 21.1% | US$9.50 | US$6.00 | US$4.30 | 3 |
| Feb ’24 | US$4.01 | US$7.33 +82.9% | 21.1% | US$9.50 | US$6.00 | US$3.73 | 3 |
| Jan ’24 | US$3.80 | US$7.75 +103.9% | 19.6% | US$9.50 | US$6.00 | US$3.94 | 4 |
| Dec ’23 | US$4.07 | US$7.75 +90.4% | 19.6% | US$9.50 | US$6.00 | US$4.00 | 4 |
| Nov ’23 | US$4.09 | US$9.50 +132.3% | 24.1% | US$12.00 | US$6.00 | US$4.20 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
VEF
SEK 2.2b
A venture capital firm specializing in early venture, emerging growth and growth capital investments.
VEFF.F
SEK 0.20
7D
0%
1Y
n/a
FinVolution Group
US$1.6b
Operates in the online consumer finance industry.
FINV
US$6.29
7D
8.1%
1Y
38.5%
ORIX
JP¥3.8t
Provides diversified financial services in Japan, the United States, Asia, Europe, Australasia, and the Middle East.
IX
JP¥107.82
7D
-0.5%
1Y
18.6%